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Abstract
Background—Congestion is a primary driver of symptoms in patients with acute heart failure
(AHF), and relief of congestion is a critical goal of therapy. Monitoring of response to therapy
through the assessment of daily weights and net fluid loss is the current standard of care, yet the
relationship between commonly used markers of decongestion and both patient reported symptom
relief and clinical outcomes are unknown.
Methods and Results—We performed a retrospective analysis of the randomized clinical trial
-Diuretic Optimization Strategy Evaluation in Acute Heart Failure (DOSE-AHF), enrolling
patients hospitalized with a diagnosis of acute decompensated heart failure (ADHF). We assessed
the relationship between 3 markers of decongestion at 72 hours—weight loss, net fluid loss and %
reduction in serum NT-proBNP level—and relief of symptoms as defined by the dyspnea visual
analog scale area under the curve (VAS AUC). We also determined the relationship between each
marker of decongestion and 60-day clinical outcomes defined as time to death, first re-
hospitalization or ER visit. Mean age was 66 years, mean EF was 35% and 27% had EF ≥50%. Of
the 3 measures of decongestion assessed, only % reduction in NT-proBNP was significantly
associated with symptom relief (r=0.13, P = 0.04). There was no correlation between either weight
loss or net fluid loss and symptom relief, (r=0.04, P=0.54 and r=0.07, P=0.27, respectively).
Favorable changes in each of the 3 markers of decongestion were associated with improvement in
time to death, re-hospitalization or ED visit at 60 days [weight: HR 0.91 (95% confidence interval
0.85, 0.97) per 4 lbs. weight lost; fluid HR 0.94 (0.90, 0.99) per 1000mL fluid loss; NT-proBNP
HR 0.95 (0.91, 0.99) per 10% reduction]. These associations were unchanged after multivariable
adjustment with the exception that % reduction in NT-proBNP was no longer a significant
predictor (HR 0.97; 0.93, 1.02). Patients with 2 or 3 markers of decongestion (above the median
value for each marker) had improved clinical outcomes versus those with 0 or 1 marker above the
median value (39.0% versus 53.8%; P=0.03).
Conclusions—Weight loss, fluid loss and NT-proBNP reduction at 72 hours are poorly
correlated with dyspnea relief. However, favorable improvements in each of the 3 markers were
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associated with improved clinical outcomes at 60 days. These data suggest the need for ongoing
research to understand the relationships between symptom relief, congestion, and outcomes in
patients with ADHF.
Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier:
NCT00577135.
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Dyspnea is the most common chief complaint among patients hospitalized with acute
decompensated heart failure (ADHF) and its relief is a primary goal of acute therapy1, 2.
Moreover, relief of dyspnea is a key endpoint in clinical trials of therapies in ADHF3, 4.
Presumably, dyspnea resolution is related to decreased pulmonary congestion5 and
guidelines recommend serial monitoring of markers of decongestion such as urine output
and changes in body weight2, 6. Reductions in body weight and fluid loss may be related to
decreased intravascular volume and should reflect decreased congestion. Elevations of
natriuretic peptides released by myocardium in response to increased wall stress, represents
a biochemical marker of increasing congestion7. Despite the intuitive concept that
decreasing congestion should result in improvement in symptoms, information regarding the
correlation between changes in markers of decongestion and symptom relief in patients with
ADHF is sparse and the results have been inconsistent8, 9 Likewise, there are few data
evaluating the relationship between markers of decongestion and short-term clinical
outcomes10
Understanding the relationship between markers of decongestion and dyspnea relief has
implications at multiple levels including patient care, the mechanistic understanding of
pulmonary congestion, the pathophysiology of dyspnea in heart failure, and the selection of
clinical trial endpoints. To address these issues the present analysis used data from the
DOSE trial to evaluate the relationships between markers of decongestion (weight loss, net
fluid loss, reduction in BNP levels) symptom relief and 60-day clinical outcomes.
Methods
Data Source
The analysis used data from the NHLBI Heart Failure Network's sponsored DOSE trial
(ClinicalTrials.gov number, NCT00577135), the study design and primary results of which
have been published previously11, 12. Briefly, DOSE was a prospective, randomized, double
blind, controlled trial, enrolling patients admitted to hospitals in 9 regional coordinating
centers and their respective satellite sites with acute decompensated heart failure (ADHF).
The study used a 2X2 factorial design randomizing patients to a strategy of high versus low
dose furosemide treatment and continuous versus intermittent bolus furosemide
administration.
Study Population
A total of 308 patients at 26 sites were enrolled between March 2008 and November 2009.
Patients admitted with a primary diagnosis of ADHF manifest by at least one sign and one
symptom of ADHF were eligible for enrollment. They were required to have a history of
chronic HF requiring outpatient oral loop diuretics. Patients with either reduced or preserved
left ventricular ejection fraction (LVEF) were included. Patients with low BNP (<250 pg/
mL) or NT-proBNP (<1000 pg/mL) were excluded, as were those with systolic blood
pressures < 90 mmHg, serum creatinine > 3 mg/dL, or requiring vasoactive medications.
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Exposure variables
Three exposure variables representing potential markers of decongestion were analyzed.
Weight loss was analyzed as the difference in weight from baseline to 72 hours in kilograms
(kg). Net fluid loss was calculated as the difference between the sum of total fluid intake and
total urine output over 72 hours in mL. Change in NT-proBNP was calculated as the %
reduction from baseline to 72 hours.
Outcomes
Symptom relief was determined by serial measurements of dyspnea at 6, 12, 24, 48, 72 and
96 hours post-randomization based on a dyspnea visual analog scale (VAS). The VAS scale
asked patients to rate their level of dyspnea from 0–100, with the higher number indicating
fewer symptoms. Change from baseline to 72 hours in dyspnea was calculated as the area
under the curve (AUC) during that time interval. A higher dyspnea VAS AUC indicated a
lower total burden of dyspnea over 72 hours.
The clinical outcome we analyzed was time to the composite of death, re-hospitalization or
emergency department (ED) visit by 60 days.
Statistical Analysis
Baseline characteristics were reported as frequency (%) for categorical variables and median
(IQR) for continuous variables. Categorical variables were compared using likelihood ratio
chi-squared tests, and continuous variables were compared using Wilcoxon signed rank
tests. The relationships among markers of decongestion and between markers of
decongestion and dyspnea were analyzed using general linear models. Pearson correlation
coefficients were calculated.
Multivariable linear regression models were used to identify potential predictors of dyspnea
relief at 72 hours among baseline variables. Candidate variables were selected based upon
clinical relevance and published literature including age, gender, race, qualifying furosemide
dose, ejection fraction, HF etiology, history of atrial fibrillation/flutter, diabetes, as well as
baseline weight, systolic blood pressure, heart rate, oxygen saturation, jugular venous
pressure, orthopnea, serum creatinine, and NT-proBNP.
Analyses comparing the number of markers of decongestion above the median value (0,1,2,
or 3) versus time to the 60-day composite event of death, rehospitalization, or ER visit were
performed using the Chi-square test.
Cox proportional hazards models were used to analyze the association between markers of
decongestion and dyspnea relief at 72 hours and the 60-day composite clinical outcome of
death, re-hospitalization or ED visit. The multivariable Cox model included the following
covariates: age, gender, baseline creatinine, HF etiology, diabetes, ejection fraction, baseline
sodium, baseline systolic blood pressure, baseline heart rate, qualifying furosemide dose,
route of administration (bolus versus continuous) and intensification strategy (high versus
low dose). A P-value of 0.05 was considered statistically significant. SAS version 9.2 (Cary,
NC) was used for all analyses.
The DOSE study was approved by the Heart Failure Network Steering, Protocol Review and
Data Safety Monitoring Committees and was approved by each participating site's
institutional review board. All patients provided written informed consent.
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Results
Among 308 patients enrolled, net fluid loss at 72 hours, net weight loss at 72 hours, and NT-
proBNP change at 72 hours were available for 242, 294, and 247 patients, respectively.
Characteristics of patients are displayed in Table 1. The median age of the study population
was 68 years. Approximately three-quarters of the population were white and three-quarters
were male. The median left ventricular ejection fraction was 30% and 27% of patients had
an ejection fraction ≥ 50%. Approximately half of the population had an ischemic etiology
for their heart failure, a history of atrial fibrillation or flutter, and a history of diabetes. Most
patients had orthopnea and elevated jugular venous pressure at baseline. The median net
fluid loss, net weight loss, and percent reduction in NT-proBNP at 72 hours were 3.8 L (IQR
1.9 - 6.0; min, max −2.8, 15.6), 6.5 lbs. (2.6 - 11.7; −42.3, 56.4), and 24.3% (−0.9 - 48.4;
−199.5, 88.7), respectively.
Relationship between markers of decongestion and dyspnea
Net fluid loss at 72 hours and net weight loss at 72 hours were modestly correlated (r=0.46,
P<.0001). The percent reduction in NT-proBNP at 72 hours did not significantly correlate
with either net fluid loss (r=0.11, P=0.11) or net weight loss (r=0.11, P=0.08). Table 2 shows
the correlation between markers of decongestion and 72 hour dyspnea VAS AUC. No
statistically significant correlation existed between net fluid loss or net weight loss and
dyspnea VAS AUC at 72 hours. The percent change in NT-proBNP at 72 hours was
modestly correlated with dyspnea VAS AUC (r=0.13, P=0.04).
When dichotomizing each marker of decongestion as above or below the median for the
group, there was no relationship between the number of markers above the median (0, 1,2 or
3) and dyspnea VAS AUC at 72 hours (P=0.47).
Baseline characteristics predicting improved dyspnea at 72-hours
Among baseline characteristics considered in a multivariable linear regression model to
identify predictors of improvement in dyspnea at 72 hours, only the presence of orthopnea at
baseline was associated with lower dyspnea VAS AUC (worse dyspnea) at 72 hours
(P=0.03).
Relationship between 72-hour dyspnea VAS AUC and clinical outcome
The dyspnea VAS AUC (for every 100 point increase) at 72-hours was associated with a
small improvement in the 60-day clinical outcome of time to first ED visit, rehospitalization
or death in a univariate Cox model (HR 0.99; P=0.01). However, after adjustment for
baseline characteristics, the association was no longer significant (HR 0.99; P=0.08).
Relationship between markers of decongestion and clinical outcome
Changes in each of the 3 markers of decongestion were significantly associated with time to
first emergency department visit, re-hospitalization or death by 60 days (Table 3). Each
1000mL increment in net fluid output was associated with a 6% reduction in risk of the 60-
day combined clinical endpoint. Each 4 lb. loss of weight at 72 hours was associated with a
9% reduction in the risk and each 10% reduction in NT-proBNP from baseline was
associated with a 5% reduction in risk. After multivariable adjustment, there was a
statistically significant, association between both the net fluid loss and weight loss markers
and reduction in the risk of time to the composite clinical endpoint. After adjustment for
covariates, percent change in NT-proBNP at 72 hours was no longer significantly associated
with the composite clinical endpoint.
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Dichotomizing each marker of decongestion as above or below the median value, we
classified patients (among those with complete data) as being above the median for 0, 1, 2 or
all 3 markers of decongestion. 211 patients were available for this analysis. In a stepwise
fashion, those with increasing numbers of markers of successful decongestion (above the
median value) had decreased rates of reaching the clinical endpoint of ED visit,
rehospitalization or death within 60 days (Figure). Probability of survival free of death, HF
hospitalization or ED visit for those with 0, 1, 2 and 3 markers of decongestion were 67%,
64%, 46%, and 38%, respectively, (Log rank P-value 0.05).
Discussion
Understanding both the relationship between measures of decongestion and symptom relief
among patients with ADHF is relevant for both patient care and investigation of new
therapies3, 4. In the present study, neither weight loss, fluid loss, nor change in natriuretic
peptide levels were closely correlated with improvement in dyspnea as measured in a
multicenter randomized clinical trial. Among baseline admission variables only orthopnea
on admission was associated with 72-hour dyspnea. However, these decongestion markers
do correlate with short-term clinical outcomes and those with multiple markers of
decongestion have better outcomes. Potential explanations for these findings include a true
lack of correlation between changes in decongestion measures and dyspnea relief, poor
sensitivity of the VAS measure of dyspnea or, likely, some combination of these factors.
Clinical Utility of Markers of Decongestion
Net fluid loss and weight loss are both measures of changes in total body fluid 8. The
correlation between these two markers was only moderate in our study, despite the fact that
they ostensibly measure the same process. However, measurement of net fluid loss in
hospitalized patients is often inaccurate because of inadvertently discarded urine,
assumptions regarding fluid volume in food products, and insensible losses. Error may be
introduced into the measure of body weight due primarily to imprecision of the scale or
using different scales at different time points. Given these considerations, it is not
unexpected that weight loss and net fluid loss would not be perfectly correlated, but they
should be reasonable approximations of total body fluid loss if done carefully. Nevertheless,
we failed to a find a correlation between each of these measures and dyspnea relief at 72
hours. One potential explanation is that dyspnea relief requires more than just volume
removal, but rather reduced pulmonary artery wedge pressure. The latter is not only a
function of left ventricular end-diastolic volume (preload) but also of afterload and
ventricular compliance13. For example, a patient with pulmonary congestion in the setting of
marked hypertension may achieve substantial symptom resolution with nitrate therapy
resulting in venodilation (preload reduction) and arterial vasodilation (afterload reduction),
even in the absence of changes status5
Correlation Between Markers of Decongestion and Dyspnea
Another potential explanation for the lack of correlation between weight loss, net fluid loss
and dyspnea relief may be related to the poor ability of currently used dyspnea instruments
to accurately capture symptom relief14. This has been an active topic in the heart failure
literature as acute symptom relief is an important endpoint in trials of new therapies for
ADHF3, 4, 14. A variety of potential tools to assess dyspnea relief have used in prior studies,
including visual analog scales, Likert scales, and numerical rating scales. Indeed, nesiritide
was approved by the Food and Drug Administration in 2001 for the treatment of ADHF,
based in part on a small improvement in dyspnea score over placebo based on a Likert
scale15. Investigators have argued that instruments to measure dyspnea presently used in
clinical trials lack sensitivity and are poorly validated14. In the present analysis, we
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measured dyspnea as area under the curve (over time) of individual measurements based on
a visual analog scale11. Recently investigators have begun to study the concept of provoked
dyspnea – that is, using postural and exercise maneuvers to discern a patient's underlying
level of dyspnea16. Hypothetically, this measurement of dyspnea at rest and with
provocation should be more sensitive to treatment effects on dyspnea than a simple, scaled,
measurement of dyspnea at a given time point which is not controlled for posture and most
commonly - but not always - performed at rest in a hospital bed14. An ongoing study
sponsored the National Heart Lung and Blood Institute's Heart Failure Network is exploring
the sensitivity of a provoked dyspnea scale to assess changes in dyspnea over time with
treatment among patients hospitalized with ADHF (Renal Optimization Strategies
Evaluation in Acute Heart Failure - ROSE-AHF. ClinicalTrials.gov NCT01132846).
Comparsion with Prior Studies
Previous studies addressing these questions have had variable results. The Ultrafiltration
Versus Intravenous Diuretics for Patients Hospitalized for Acute Decompensated Heart
Failure (UNLOAD) trial comparing ultrafiltration and intravenous diuretic therapy reported
significantly greater reduction in body weight and increased fluid loss in the ultrafiltration
arm; however there was no difference in the dyspnea score between the two therapies 8. In
contrast, a post-hoc analysis of the Efficacy of Vasopressin Antagonism in Heart Failure
Outcome Study with Tolvaptan (EVEREST) trial did demonstrate a statistically significant,
albeit weak, correlation between weight loss and dyspnea (r=0.20). However, there was no
correlation between weight loss and subsequent clinical outcomes9. Similarly, in the
Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization
Effectiveness) ESCAPE trial there was no association between weight loss and inpatient or
outpatient clinical events. However, those in the highest tertile of weight loss had a
significantly decreased orthopnea score.10
This study found an association between improvement in dyspnea at 72 hours and clinical
outcomes at 60 days. These data are similar to prior work by Metra and colleagues
demonstrating a relationship between dyspnea improvement and post-discharge clinical
outcomes17, 18. However, in the current study, this association was no longer statistically
significant after adjusting for baseline characteristics.
Markers of Decongestion and Short Term Clinical Outcomes
The finding of a moderate correlation between both weight loss and net fluid loss and 60-
day death, re-hospitalization or emergency department visit differs from findings in the
ESCAPE trial in which there was no correlation between weight loss and clinical outcomes.
One potential reason for the difference is that the ESCAPE cohort was sicker and, hence,
their degree of illness may have mitigated the effects of volume removal as an independent
predictor of clinical outcomes10. In comparison, patients undergoing ultrafiltration in the
UNLOAD trial, had decreased risk of 90-day clinical events (re-hospitalization, unscheduled
physician visits) in conjunction with greater average volume removal8.
The absence of a significant relationship (adjusted for baseline variables) between percent
change in NT-proBNP at 72 hours and 60-day clinical outcomes was unexpected as several
small studies have previously documented such a relationship19–22. Given that there still
appeared to be a trend towards improved outcomes among those with greater reductions, this
finding may represent a limitation of our sample size.
Finally, the study found that for each additional marker of decongestion greater than the
median value, event rates improve noticeably. This suggests that a strategy of evaluating all
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available data concerning a given patient's volume status is preferable than focusing on only
one such as the change in weight.
Clinical Implications
Our study has several important clinical implications. Individual markers of decongestion as
currently measured them do not correlate well with symptom relief. This finding may reflect
the heterogeneity of acute heart failure syndromes and/or the lack of sensitivity of current
dyspnea instruments. However, multiple markers of decongestion in the same patient are
associated with improved clinical outcomes such as fewer ED visits, readmissions or death
compared to fewer or no markers of decongestion. These results suggest that measuring
markers of decongestion continue to have clinical utility in the care of hospitalized patients,
but should be interpreted in the context of patient reported symptoms and physical
examination findings.
Limitations
This was a post-hoc retrospective observational study of a clinical trial. There may be
residual or unmeasured confounding even after multivariable adjusting. Additionally, the
sample size was relatively small which decreased our ability to detect a difference when
performing the analysis. Measurement errors may have been introduced in determining net
fluid balance based on human error. For example, urine output may not fully represent all
fluid loss given other insensible losses. Likewise, utilization of different weight scales or
non-standardization of time-of-day for weight measurement may have introduced error into
the weight loss variable.
However, our results are meant to inform real-world practice where such measurement is
likely to occur. Since this was a clinical trial, exclusion criteria were implemented in part
related to stability (systolic blood pressure > 90 mmHg, lack of vasoactive medications) and
renal function (Serum Creatinine < 3 mg/dL). These exclusions could limit the
generalizability of these results to less stable patients or those with marginal renal function.
Conclusion
Among three markers of decongestion, net fluid loss at 72 hours, weight loss at 72 hours and
% reduction in NT-proBNP at 72 hours, only % reduction in NT-proBNP was correlated,
albeit modestly, with symptom relief. Among several baseline characteristics considered,
only orthopnea at admission was associated with change in dyspnea at 72 hours. Finally,
after adjustment for potential confounders, only net fluid loss and weight loss at 72 hours
were modestly associated with time to death, re-hospitalization or ED visit at 60 days. These
data underscore the current knowledge gaps regarding the relationship between dyspnea,
congestion, and outcomes in patients with ADHF. Greater understanding of the biology of
dyspnea and decongestion in ADHF will be critical if these concepts are to continue to be
targets for drug development.
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Figure.
Relationship Between Number of Markers of Decongestion Above Median * and time to 60-
day Risk of ED Visit, Rehospitalization or Death. (ED: emergency department).
*
 Median net fluid loss 3.8 L, median net weight loss 6.5 lbs, median % reduction in NT-
proBNP 24.3%.
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Table 1
Baseline characteristics
Variable1 All Patients
N=308
Age, years 68 (56, 77)
Male 226 (73.4)
White race 222 (72.1)
Weight, lbs. 206 (176, 242)
Baseline furosemide dose, mg 120 (80, 160)
Left ventricular ejection fraction, % 30 (20, 50)
Ischemic etiology 176 (57.1)
Atrial fibrillation/ flutter 162 (52.6)
Baseline systolic blood pressure, mmHg 115 (104, 132)
Baseline heart rate, bpm 76 (69, 85)
Baseline oxygen saturation, % 96 (94, 98)
JVP ≥ 8 cm 267 (91.4)
Orthopnea ≥ 2 pillows 229 (77.9)
Sodium, mEq 139 (136, 141)
BUN, mg/dL 31 (20, 50)
Creatinine, mg/dL 1.43 (1.10, 1.83)
1Categorical variables reported as frequency (percent) and continuous variables reported as median (interquartile ratio).
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Table 2
Correlation between markers of decongestion and change in dyspnea VAS AUC at 72 hours
Marker of
Decongestion
N r P-value
Net fluid loss at 72 hours 239 0.07 0.27
Weight loss at 72 hours 291 0.04 0.54
% reduction in NT-proBNP at 72 hours 246 0.13 0.04
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Table 3
Unadjusted and adjusted relationship between change in markers of decongestion at 72 hours and 60-day risk
of emergency department visit, re-hospitalization, or death.
Marker of
Decongestion
Unadjusted HR1
(95% CI)
Adjusted HR2
(95% CI)
Net fluid loss at 72 hours (per 1000 ml) 0.94 (0.88, 0.99) 0.93 (0.88, 1.00)
Weight loss at 72 hours (per 4 lbs) 0.91 (0.85, 0.97) 0.92 (0.85, 0.98)
% reduction in NT-proBNP at 72 hours (per 10%) 0.95 (0.91, 0.99) 0.97 (0.93, 1.02)
1
Hazard ratio from the unadjusted cox regression model
2
Hazard ratio from the adjusted cox regression mode
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